# Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

> **NCT02330562** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 121 (actual)

## Conditions studied

- Malignant Glioma
- Glioblastoma

## Interventions

- **DRUG:** MRZ
- **DRUG:** BEV

## Key facts

- **NCT ID:** NCT02330562
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2021-06-02
- **Final completion:** 2021-06-02
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2022-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02330562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02330562, "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02330562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*